These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 2468602)

  • 21. Treating tumor-bearing mice with low-dose gamma-interferon plus tumor necrosis factor alpha to diminish immune suppressive granulocyte-macrophage progenitor cells increases responsiveness to interleukin 2 immunotherapy.
    Pak AS; Ip G; Wright MA; Young MR
    Cancer Res; 1995 Feb; 55(4):885-90. PubMed ID: 7850804
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lessons from Coley's Toxin.
    Tsung K; Norton JA
    Surg Oncol; 2006 Jul; 15(1):25-8. PubMed ID: 16814541
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Immunity against cancer--a critical review of recent progress--].
    Yamamura Y
    Gan To Kagaku Ryoho; 1983 Feb; 10(2 Pt 2):311-9. PubMed ID: 6192758
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Cytokines and monoclonal antibodies. Immunologic approaches to tumor therapy].
    Pfreundschuh M
    Fortschr Med; 1986 Dec; 104(47-48):973-6. PubMed ID: 2434398
    [No Abstract]   [Full Text] [Related]  

  • 25. A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma.
    Kimura H; Yamaguchi Y
    Cancer; 1997 Jul; 80(1):42-9. PubMed ID: 9210707
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA; Hu P; Epstein AL
    Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combinations of anticancer drugs and immunotherapy.
    Mitchell MS
    Cancer Immunol Immunother; 2003 Nov; 52(11):686-92. PubMed ID: 12942200
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic properties of biological response modifiers. A discussion of preclinical and clinical studies.
    Talmadge JE
    Contrib Gynecol Obstet; 1989; 17():49-62. PubMed ID: 2495895
    [No Abstract]   [Full Text] [Related]  

  • 29. Tumor necrosis factor alpha mediates the antitumor effect of combined interleukin-2 and whole body hyperthermia.
    Fritz KL; Koziol S; Fabian DF; Lefor AT
    J Surg Res; 1996 Jan; 60(1):55-60. PubMed ID: 8592432
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapy of disseminated NK-resistant tumor by the synergistic effects of recombinant interleukin-2 and tumor necrosis factor.
    Agah R; Malloy B; Sherrod A; Bean P; Girgis E; Mazumder A
    J Biol Response Mod; 1988 Apr; 7(2):140-51. PubMed ID: 3258905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interleukin-2 based immunotherapy in patients with metastatic renal cell carcinoma.
    Donskov F
    Dan Med Bull; 2007 Nov; 54(4):249-65. PubMed ID: 18208677
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Antitumor effect of biological factors and their response].
    Yamazaki M
    Nihon Rinsho; 1987 May; 45(5):1144-55. PubMed ID: 2442437
    [No Abstract]   [Full Text] [Related]  

  • 33. Combined chemo- and immunotherapy of tumors induced in mice by bcr-abl-transformed cells.
    Sobotkova E; Duskova M; Tachezy R; Petrackova M; Vonka V
    Oncol Rep; 2009 Mar; 21(3):793-9. PubMed ID: 19212641
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Cytokines as immunotherapy in cancer].
    van der Schelling GP; Ijzermans JN; Marquet RL; Jeekel J
    Ned Tijdschr Geneeskd; 1992 Apr; 136(14):681-5. PubMed ID: 1373229
    [No Abstract]   [Full Text] [Related]  

  • 36. Marrying immunotherapy with chemotherapy: why say IDO?
    Muller AJ; Prendergast GC
    Cancer Res; 2005 Sep; 65(18):8065-8. PubMed ID: 16166276
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination cytokine immunotherapy with tumor necrosis factor alpha, interleukin 2, and alpha-interferon and its synergistic antitumor effects in mice.
    McIntosh JK; Mulé JJ; Krosnick JA; Rosenberg SA
    Cancer Res; 1989 Mar; 49(6):1408-14. PubMed ID: 2784349
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjuvant treatment of minimal residual tumors. A comparison of chemotherapy and immunotherapy.
    Mathé G; Reizenstein P; Eriguchi M
    Suppl J Med Oncol Tumor Pharmacother; 1988; 1():75-92. PubMed ID: 3074229
    [No Abstract]   [Full Text] [Related]  

  • 39. Interleukins, interferons and tumor necrosis factor in cancer treatment.
    Krigel RL
    AAOHN J; 1987 Apr; 35(4):159-62. PubMed ID: 2950885
    [No Abstract]   [Full Text] [Related]  

  • 40. [Immunotherapy of tumors using interleukin-2 and lymphokine-activated killer cells].
    Jost LM; Gmür J; Oelz O; Sauter C; Stahel RA
    Schweiz Med Wochenschr; 1988 Feb; 119(5):137-43. PubMed ID: 3266369
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.